This prestigious international event took place on November 19 and 20 at the Four Seasons Hotel Manama, with the presence of over 500 attendees and sponsored by Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister of the Kingdom of Bahrain. The forum included a global competition known as the Global Fundraising Stage, which brought together innovative startups from numerous countries around the world.
The presentation of PlusVitech was conducted by Dr. Vicente Salinas, CEO, and Fran Guillén, General Manager, before an international jury composed of 20 distinguished investors from Bahrain, Dubai, India, Pakistan, Italy, Korea, among others. The outstanding performance of the Seville-based company allowed them to emerge as winners, enabling PlusVitech to enter, alongside two other international companies, the due diligence phase with the WBAF Fund.
In the words of Fran Guillén: “It is a great honor to receive this prestigious award in an international competition with companies of such high caliber. Many years of effort have been necessary for our revolutionary cancer drug to reach the maturity required to achieve such recognition, and thanks to the new investment round, we can bring it to market soon,” commented Fran Guillén.
Additionally, Guillén highlighted: “It has been an extraordinary experience to speak with the Minister of Finance of Bahrain, meet Feryal Nass and the President of the Bahrain Chamber of Commerce, as well as numerous international investors and top-level experts who have shown great interest in PlusVitech.”
For his part, Dr. Vicente Salinas expressed: “We appreciate this great recognition, which motivates us and helps us advance toward our goal of making our drug available to patients suffering from advanced types of cancer who currently have no effective and safe treatment alternatives.”
In addition to this achievement, PlusVitech was awarded the European Commission’s Seal of Excellence at the end of 2023 and is included in its recommended investment platform. Recently, the company signed an investment agreement with Nanoform (Nordiq NASDAQ: NAHOFH), a Finnish company that has joined as an investor in PlusVitech. With this new funding round, PlusVitech seeks to complement its capital with more investors to secure the necessary funds that will enable its innovative drug PVT-01 to reach the market, expected in 2026.
About PlusVitech
PlusVitech is a leading Seville-based company in the development of innovative drugs for cancer treatment. Founded with the mission to transform the therapeutic landscape for patients with advanced cancer, PlusVitech focuses on the research and development of compounds that offer effective and safe alternatives to conventional therapies. With a multidisciplinary team of experts in biotechnology, pharmacology, and business, the company is committed to bringing cutting-edge medical solutions to the global market. For more information: https://www.plusvitech.com/
About the World Business Angels Investment Forum (WBAF)
The World Business Angels Investment Forum (WBAF), as an affiliated partner to the Global Partnership for Financial Inclusion (GPFI) of the G20, is one of the most prestigious platforms worldwide for connecting innovative startups with a global network of angel investors. Held annually in various cities around the world, WBAF brings together entrepreneurs, investors, industry leaders, and authorities to foster investment in high-potential projects and promote sustainable economic growth. For more information: https://www.wbaforum.org/
